NCT05392764 (EMPA-AHF) is a Phase 3 clinical trial of Empagliflozin 10 MG in Acute Heart Failure, sponsored by Juntendo University.

Who is sponsoring NCT05392764?

NCT05392764 is sponsored by Juntendo University.

What drugs are being tested in NCT05392764?

Interventions in NCT05392764: Empagliflozin 10 MG, Placebo.

What condition does NCT05392764 study?

NCT05392764 studies Acute Heart Failure.

Is NCT05392764 still recruiting?

NCT05392764 is currently recruiting now. Last updated 13 February 2026.

Last reviewed 2026-02-13 · How we verify

NCT05392764: EMPA-AHF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Recruiting now Phase 3 Last updated 13 February 2026

What this trial tests

Phase 3 trial testing Empagliflozin 10 MG in Acute Heart Failure in 444 participants. Currently enrolling.

Timeline

10 September 2022

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Juntendo University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	444
Start date	10 September 2022
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	69 locations across Japan

Drugs / interventions tested

Empagliflozin 10 MG — full drug profile →
Placebo

Conditions studied

Acute Heart Failure — all drugs for Acute Heart Failure →

Sponsor

Juntendo University

Who can join

20 and older, any sex, with Acute Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.
Preda A, Montecucco F, Carbone F, Carbone F, et al · · 2024 · cited 76× · PMID 38456601 · DOI 10.1093/cvr/cvae047
SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
Ul Amin N, Sabir F, Amin T, Sarfraz Z, et al · · 2022 · cited 19× · PMID 36553880 · DOI 10.3390/healthcare10122356
Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici.
Bhandari M, Pradhan A, Vishwakarma P, Singh A, et al · · 2024 · PMID 39492976 · DOI 10.4330/wjc.v16.i10.550

Verify or expand the search:

Other trials of Empagliflozin 10 MG

Trials testing the same drug.

NCT03867487 — SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease · Phase 2 · not yet recruiting
NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
NCT06706791 — Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II · Phase 4 · recruiting
NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
NCT06030843 — The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 · Phase 2, PHASE3 · recruiting

Other recruiting trials for Acute Heart Failure

Currently open trials in the same condition.

NCT06587854 — a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart Failure · recruiting
NCT07008365 — The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure · Phase 3 · recruiting
NCT06465498 — Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography · NA · recruiting
NCT06597331 — Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital · recruiting
NCT06166654 — Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload · Phase 4 · recruiting

Other Juntendo University trials

Trials by the same sponsor.

NCT04950842 — Induction of Transplant Tolerance in LDLT Via iTS · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05392764 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juntendo University
Last refreshed: 13 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05392764.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing